CNBX News and Press, Cannabics Pharmaceuticals Inc From 04/26/21

Cannabics Pharmaceuticals Launches a New Research Program to develop a Melanoma Treatment Drug Candidate for FDA Approval Track PR Newswire TEL AVIV , Israel and BETHESDA, Maryland, April 26, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC...

Cannabics Pharmaceuticals Launches Psilocybin and Psilocin Research Program PR Newswire TEL AVIV , Israel and BETHESDA, Md., April 20, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer r...

Cannabics Pharmaceuticals to Initiate in-vivo Dose Response Study on Proprietary Colorectal Cancer Drug Candidate RCC-33 PR Newswire TEL AVIV , Israel and BETHESDA, Maryland, March 31, 2021 /PRNewswire/--Cannabics Pharmaceuticals Inc. (OTCQB: CNBX)...

Cannabics Pharmaceuticals (CNBX) announces results of its in-vivo study evaluating the efficacy of the company's proprietary drug candidate RCC-33 in prolonging survival rate in mice inoculated with human colorectal cancer cells.Study results indicate a 35% prolonged survival rate in mice exp...

Cannabics Pharmaceuticals' Drug Candidate RCC-33 Prolongs Survival Rate in Mice Inoculated with Human Colorectal Cancer Cells PR Newswire TEL AVIV , Israel and BETHESDA, Md., March 17, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNB...

Mexico with 121 million citizens will likely legalize cannabis by April of this year opening the door to the largest population for potential customers; This will be a game-changing tipping point for legalization of cannabis around the world and especially throughout Latin America; ...

Cannabics Pharmaceuticals' in-vivo Tumor Inhibitory Effect Study Concludes with a Statistical Significance of p ≤ 0.016 PR Newswire TEL AVIV , Israel and BETHESDA, Maryland, Feb. 17, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB...

Cannabics Pharmaceuticals ([[CNBX]]) announces the final results of its in-vivo study evaluating the efficacy of the company's proprietary drug candidate RCC-33 for the treatment of colorectal cancer in nude-mice.The final study results showed a significant and robust inhibitory effect on tum...

Cannabics Pharmaceuticals' in-vivo Study concludes with a 33% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer PR Newswire TEL AVIV , Israel and BETHESDA, Maryland, Feb. 16, 2021 /PRNewswire/ -- Can...

Cannabics Pharma ([[CNBX]] +9.7%)  has obtained positive interim results for its ongoing in-vivo study evaluating the efficacy of the company's RCC-33 for colorectal cancer in nude-mice.The interim results show a 27% reduction in tumor volume in mice exposed to RCC-33 in comparison ...